Furthermore, while PHD1 and PHD2 were largely unchanged in AML subsets with diverse cytogenetic abnormalities compared to non-leukemic controls, the relative PHD2 expression was overall higher in all AML subsets compared to PHD1 (Fig. 1b). This evidence concerns the gene EGLN2 and acute myeloid leukemia.